U.S. Medicaid rule ends coverage of hormones and surgeries for gender-related care for minors

On October 13, 2026, a rule will take effect in the United States that leaves little room for interpretation: the federal health coverage programs Medicaid and the Children’s Health Insurance Program (CHIP) will no longer cover puberty blockers, cross-sex hormones, or surgeries when used for gender transition in minors. The rule, established by the Centers for Medicare & Medicaid Services (CMS), part of the U.S. Department of Health and Human Services (HHS), was published in the Federal Register on August 13, 2026. Since then, reactions have ranged from relief to outrage — and the first lawsuits have already been filed.

What exactly the rule changes

The rule is narrow but bluntly worded. For Medicaid beneficiaries under 18 and CHIP participants under 19, the federal contribution toward puberty blockers, hormone therapy, and surgical procedures specifically intended for gender transition will end. Young people who are already taking hormones are covered by a transitional arrangement: they will retain federal coverage for a maximum of six months, exclusively for a medically supervised tapering-off period. Treatment for intersex conditions (DSD), other medical indications, and care for complications remain unaffected, as does mental health care that Medicaid and CHIP already cover. It is also important to note what the rule does not do: it does not prohibit practitioners or clinics from providing anything. A state that wants to use its own funds may continue to do so — only the federal contribution will disappear. For poorer families in states that rely heavily on those federal matching funds, the practical difference is often the difference between having access and not having access. American journalist Benjamin Ryan follows such decisions and the lawsuits surrounding them in his Hazard Ratio newsletter.

Legal opposition: who is challenging the rule and why

In early October 2026, four low-income families in New Hampshire, represented by the ACLU of New Hampshire, filed a lawsuit against the Trump administration. Their argument: their children are losing access to care for which no alternative is available, while they cannot afford to pay for it themselves. The rule is also controversial from an administrative-law perspective. Analysts at the health publication STAT News pointed out in mid-August that the legal basis on which CMS relies — the claim that gender-transition care for minors is not demonstrably “medically necessary” — will itself become the subject of litigation, because the law normally gives CMS little room to categorically exclude entire treatment categories in this way. The federal court will therefore not primarily be deciding whether puberty blockers are “good” or “bad,” but whether an administrative agency such as CMS is actually allowed to make this decision without intervention by Congress.

The heart of the dispute: how strong is the evidence?

Underlying the legal battle is a substantive question that has long been debated outside the U.S. as well: how well supported are puberty blockers, hormones, and surgery for minors with gender dysphoria? The United Kingdom’s Cass Review concluded that the evidence base is “strikingly weak,” Sweden tightened its guidelines following the SBU report, and Finland and Norway have also been moving toward a more cautious approach for years. CMS cites similar concerns in its explanation of the rule. Yet not every argument made by the current administration is equally robust: in late September, NPR dissected a separate HHS report on “gender ideology” and found that it had not been peer-reviewed, used figures from an activist advocacy organization, and omitted important context. The fact that a government is simultaneously promoting a poorly substantiated ideological report and introducing a stricter funding rule that does rely on recognized evidence reviews shows that in the U.S., being “critical of the evidence base” has itself become just as much a political weapon as the affirmative model it criticizes. For anyone seeking to follow the issue factually, that distinction — between a substantiated evidence review and a political report that happens to point in the same direction — is precisely what matters. gendermedia.nl explains how to critically assess research and statistics in gender news yourself.

What this means for the Netherlands

A federal coverage rule in the U.S. does not change the Dutch healthcare system. What Dutch health insurers cover for transition-related care is outlined at trans-nederland.nl. But the underlying debate is undeniably cross-border: here too, the development of the Dutch quality standard for transgender care came under criticism because health insurers were not involved in its development at the time and “informed consent” was given its own, later interpretation. The American episode is also not an isolated event: earlier this year, the Trump administration put forward Heidi Overton, an outspoken critic of gender-affirming care, as a candidate for FDA commissioner, and in Texas, following a ten-million-dollar settlement, the first American detransition clinic opened. The Medicaid rule fits into that same broader shift in American gender care — with one crucial difference: this is not about a lawsuit or an appointment, but about who will still have access to care, regardless of what one thinks of that care.

Sources

• AJMC, "CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care", August 2026. ajmc.com
• STAT News, "How will legal challenges fare against CMS rule on gender-affirming care?", August 14, 2026. statnews.com
• ACLU New Hampshire, press release "New Hampshire families sue to stop the Trump administration from cutting off medical care for transgender youth on Medicaid", October 2026. aclu-nh.org
• NPR, "What's behind HHS claims that gender-affirming care 'may' radicalize", September 30, 2026. npr.org